论文部分内容阅读
目的:通过比较血清中早期前列腺癌抗原-2(EPCA-2)与前列腺特异性抗原(PSA)在前列腺癌(PCa)诊断中的特异性与敏感性,研究血清中EPCA-2对诊断PCa的临床意义。方法:收集非前列腺疾病患者20例(作为A组),BPH患者56例(作为B组),PCa患者44例(作为C组),采用酶联免疫吸附实验(ELISA)分别检测三组患者血清中EPCA-2和PSA水平,进行统计学分析。结果:①C组患者血清中EPCA-2和PSA水平分别与A组和B组患者的进行比较,均显著增高,差异有统计学意义(P<0.01)。②A组血清中EPCA-2水平均≤分界点(30μg/L)。③以30μg/L为分界点,EPCA-2对PCa诊断的特异性为92.1%,敏感性为93.2%;以4μg/L为分界点,PSA对PCa诊断的特异性为55.3%,敏感性为79.5%;PSA结合fPSA/tPSA(以0.15为分界点),对PCa诊断的特异性为78.9%,敏感性为68.2%。结论:EPCA-2作为新的诊断PCa的肿瘤标志物,较PSA具有更高的特异性和敏感性,对临床PCa的诊断具有重要意义。
Objective: To compare the specificity and sensitivity of EPCA-2 and PSA in the diagnosis of prostate cancer (PCa) in serum, to study the effect of EPCA-2 in serum on the diagnosis of PCa Clinical significance. Methods: Twenty patients with non-prostatic diseases (group A), 56 patients with BPH (group B) and 44 patients with PCa (group C) were enrolled in this study. Enzyme-linked immunosorbent assay (ELISA) In EPCA-2 and PSA levels, for statistical analysis. Results: ① The serum levels of EPCA-2 and PSA in group C were significantly higher than those in group A and group B, respectively, with statistical significance (P <0.01). ② The serum levels of EPCA-2 in group A were all ≤ ≤ (30 μg / L). (3) With 30μg / L as the cut-off point, the specificity of EPCA-2 for PCa diagnosis was 92.1% and the sensitivity was 93.2%. The specificity of PSA for PCa diagnosis was 4% (4μg / L) 79.5%; PSA combined fPSA / tPSA (0.15 as the cut-off point), the diagnosis of PCa specificity was 78.9%, the sensitivity was 68.2%. Conclusion: EPCA-2 is a new tumor marker for PCa diagnosis. It has higher specificity and sensitivity than PSA and is of great significance for the diagnosis of PCa.